Nandrolone cyclohexanecarboxylate

Nandrolone cyclohexanecarboxylate
Clinical data
Trade namesNor-Durandron, Norlongandron
Other namesNSC-3351; Nandrolone hexahydrobenzoate; 19-Nortestosterone 17β-cyclohexanecarboxylate
Routes of
administration		Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen
Identifiers
IUPAC name
  • [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] cyclohexanecarboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H36O3
Molar mass384.560 g·mol−1
3D model (JSmol)
SMILES
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@H]35
InChI
  • InChI=1S/C25H36O3/c1-25-14-13-20-19-10-8-18(26)15-17(19)7-9-21(20)22(25)11-12-23(25)28-24(27)16-5-3-2-4-6-16/h15-16,19-23H,2-14H2,1H3/t19-,20+,21+,22-,23-,25-/m0/s1
  • Key:AQMOXBCKEKPDRF-YNFNDHOQSA-N

Nandrolone cyclohexanecarboxylate (brand names Nor-Durandron, Norlongandron; former developmental code name NSC-3351), or nandrolone hexahydrobenzoate, also known as 19-nortestosterone 17β-cyclohexanecarboxylate, is a synthetic androgen and anabolic steroid and a nandrolone ester that has been marketed by Ferring Pharmaceuticals since at least 1961.[1][2][3][4][5]

Relative affinities (%) of nandrolone and related steroids
CompoundPRARERGRMRSHBGCBG
Nandrolone20154–155<0.10.51.61–160.1
Testosterone1.0–1.2100<0.10.170.919–823–8
Estradiol2.67.91000.60.138.7–12<0.1
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, dexamethasone for the GR, aldosterone for the MR, dihydrotestosterone for SHBG, and cortisol for CBG. Sources: See template.

See also

References

  1. ↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 660–. ISBN 978-1-4757-2085-3.
  2. ↑ Mozayani A, Raymon L (15 October 2003). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 501–. ISBN 978-1-59259-654-6.
  3. ↑ Challener CA (1 December 2001). Chiral Drugs. Wiley. p. 131. ISBN 978-0-566-08411-9.
  4. ↑ Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (2 July 2013). Therapie innerer Krankheiten. Springer-Verlag. pp. 409–. ISBN 978-3-662-10489-7.
  5. ↑ Svenska läkartidningen. Sveriges Läkarförbund. 1961. p. 1961.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.